Lessons learned from investigator-initiated clinical trials for localized pancreatic cancer. J Surg Oncol 2022 Jan;125(1):69-74
Date
12/14/2021Pubmed ID
34897709DOI
10.1002/jso.26756Scopus ID
2-s2.0-85120941585 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Investigator-initiated trials (IITs) are clinical trials in which the clinician is both the sponsor and the investigator. IITs have also been developed to test strategies designed to optimize existing therapies or treatment approaches that may not be supported by industry sponsors or may be too novel to gain the consensus to be supported by cooperative groups. The role of the investigator is comprehensive and includes protocol development, securing funding for the administration of the trial, recruitment and monitoring of subjects, and assurance for the protection of human subjects. We will briefly review the importance of surgeons in developing IITs and provide insights into logistical barriers from conception to completion of the trial.
Author List
Tsai S, Evans DBAuthor
Douglas B. Evans MD Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Clinical ProtocolsClinical Trials as Topic
Humans
Pancreatic Neoplasms
Surgical Oncology
